

Custom Antibody Services

Empowering Scientific Discoveries

Service Features

The Pioneer in Novel Modifications Your Premier Destination for Custom PTM Antibodies

We specialize in creating custom antibodies for a wide range of novel acylation modifications, including lactylation, crotonylation, succinylation, and more. PTMab boasts the world's most extensive collection of PTM antibodies, featuring over 30 different modification types.

An Impact Factor Amplifier Achieve High-Impact Publications with Our Exceptional Success Rate

Our custom antibodies have achieved remarkable success in development, with a staggering 96% success rate over the past four years, covering over 28 different species. The average impact factor of collaborative articles reached an impressive 10+ in 2022.

Custom Antibody Solution 1

Rabbit Polyclonal Antibody Generation (Unmodified & PTM-Specific)





Antigen Preparation

Rabbit Immunization



Serum Screening and Purification






Phases	Package A Unmodified Antibody	Package B PTM- Specific Antibody	Deliverables
Antigen Preparation (2~3 weeks)	2 Antigenic polypeptides QC by in-house mass spectrometry facility	2 Antigenic polypeptides 1 Unmodified control polypeptide QC by in-house mass spectrometry facility	1 mg each peptide
Immunization (8~11 weeks)	4 Rabbits 1 primary injection + 5 booster injections	6 Rabbits 1 primary injection + 5 booster injections	7
Serum Screening & Purification (1~2 weeks)	Serum primary screening by ELISA and WB. Affinity purification against Protein A and antigen.	Serum primary screening by ELISA and WB. Affinity purification against Protein A and antigen, followed by depletion in an unmodified polypeptide affinity column	1
Validation (1~2 weeks)	QC Standards: 1. Minimum antibody titer of 1:50,000 as determined by ELISA; 2. Test one of the following applications: WB, ICC, or IHC.	QC Standards: 1. Minimum antibody titer of 1:50,000 as determined by ELISA; 2. Dot Blot: Recognition of the modified antigen polypeptide at a minimum of 20 ng. The antibody should demonstrate at least 10- fold higher selectivity for the modified peptide over the unmodified peptide. 3. Endogenous target protein detected by WB.	2 mg antibody and development report.

Custom Antibody Solution 2

Recombinant Rabbit Monoclonal Antibody Generation (Unmodified & PTM-Specific)



Package B

Phases	Package A Unmodified Antibody	Package B PTM- Specific Antibody	Deliverables
Antigen Preparation (2~3 weeks)	2 Antigenic polypeptides QC by in-house mass spectrometry facility	2 Antigenic polypeptides 1 Unmodified control polypeptide QC by in-house mass spectrometry facility	1 mg each peptide
Immunization (8~11 weeks)	4 Rabbits 1 primary injection + 5 booster injections	6 Rabbits 1 primary injection + 5 booster injections	1
Serum Screening & Purification (1~2 weeks)	Serum primary screening by ELISA and WB. Affinity purification against Protein A and antigen	Serum primary screening by ELISA and WB. Affinity purification against Protein A and antigen, followed by depletion in an unmodified polypeptide affinity column	1
B Cell Panning & Screening (2 weeks)	B cell panning and ELISA screening for positive clones	B cell panning and ELISA screening for positive clones	1
Antibody Cloning & Recombinant Antibody Production (7-8 weeks)	Select the best positive clone for sequencing, IgG cloning and recombinant antibody production	Select the best positive clone for sequencing, IgG cloning and recombinant antibody production	1
Validation (1~2 weeks)	QC Standards: 1. Minimum antibody titer of 1:50,000 as determined by ELISA; 2. Endogenous target protein detected by WB.	QC Standards: 1. Minimum antibody titer of 1:50,000 as determined by ELISA; 2. Dot Blot: Recognition of the modified antigen polypeptide at a minimum of 20 ng. The antibody should demonstrate at least 10- fold higher selectivity for the modified peptide over the unmodified peptide. 3. Endogenous target protein detected by WB.	2 mg antibody and development report


Featured Case Studies

Article

Cancer Cell

Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis

PMID	Impact Factor	Journal	Application	Custom Antibody
32049046	38.585	Cancer cell	WB	MYC S67p




PMID Impact Factor Journal Application Custom Antibody AML1-ETO meR43 ALL1-ETO meR43 AmL1-ETO meR43 ALL1-ETO meR43 31612207 17.7 Nature Communications WB/ChIP K43me-AMI 1 B300 Ballot and the state of the state	nature	ATIONS	ARTICLE Menu/Andrews/Attentionary Constrained Protein lysine 43 meth AML1-ETO transcriptio			AML1-ETO	
31612207 17.7 Nature Communications WB/ChIP K43me-AMI 1	PMID		Journal	Application		AML1-ETO aceK43	
RefSeq DIP2B *	31612207	17.7	Nature Communications	WB/ChIP	K43me-AML1	p300	Engendarie e., 18., a service addididation of a state state of a state state addition of a state of

NAR Breakthrough Article

GLP-catalyzed H4K16me1 promotes 53BP1 recruitment to permit DNA damage repair and cell survival

	lmpact Factor	Journal	Application	Custom Antibody
31612207	19.16	Nucleic Acids Research	WB/IF/ChIP	H4K16me1



About Us

Established in 2010, PTM BIO has emerged as a pioneering force in the fields of epigenetics and proteomics. Led by distinguished scientists, our mission is to develop and provide innovative research products and services that revolutionize our comprehension, diagnosis, and treatment of human diseases. Our integrated platform, encompassing proprietary PTM reagents, sophisticated mass spectrometry expertise, and advanced bioinformatics tools, has been profoundly benefiting biomedical and pharmaceutical research, as demonstrated by continuous high-profile publications and long-term collaborative relationship with top tier drug discovery organizations. We are well positioned to apply state-of-the-art proteomics strategies to improve therapy selection for patients, and to discover a brave new world of medical possibilities.

PTM BIO

www.ptmbio.com Tel: +1 312-802-6843 Email: info@ptmbio.com